RedHill Biopharma (RDHL) Reports Initiation of Phase IIa Study with ABC294640 (YELIVA) for Cholangiocarcinoma at Mayo Clinic and MD Anderson
Tweet Send to a Friend
RedHill Biopharma Ltd. (NASDAQ: RDHL), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary drugs ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
